Clinical Pharmacology and Drug Toxicity — MCQs
On this page
Hemodialysis is not useful in which of the following conditions?
Which of the following congenital malformations is seen in a child born to a mother treated with oral anticoagulants?
Which of the following drugs can cause osteonecrosis when administered intravenously?
Sclerosing cholangitis is a known side effect caused by which of the following drugs?
What is the treatment for Type II paralysis in organophosphorus poisoning?
All of the following drugs require dose reduction in cirrhosis except?
What is the mechanism of action of pralidoxime?
Which of the following is used to treat cyanide poisoning?
What drug is associated with the following adverse drug reaction (ADR)?
Which of the following drugs exhibits a therapeutic window phenomenon?
Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs
Question 381: Hemodialysis is not useful in which of the following conditions?
- A. Digitalis toxicity (Correct Answer)
- B. Theophylline toxicity
- C. Salicylate toxicity
- D. All of the above
Explanation: To determine if a drug can be removed by hemodialysis, it must have a **low volume of distribution (Vd)**, low molecular weight, and low protein binding. **1. Why Digitalis toxicity is the correct answer:** Digitalis (Digoxin) has an exceptionally **large volume of distribution (Vd > 5-7 L/kg)** because it binds extensively to tissue proteins, particularly in the myocardium and skeletal muscle. Since most of the drug is sequestered in the tissues rather than circulating in the plasma, hemodialysis is ineffective at removing it. The definitive treatment for severe digitalis toxicity is **Digoxin-specific antibody fragments (DigiFab).** **2. Why the other options are incorrect:** * **Theophylline toxicity:** Theophylline has a low Vd and low molecular weight. Hemodialysis (or hemoperfusion) is highly effective and indicated in severe cases (e.g., serum levels >100 mcg/mL in acute ingestion or seizures). * **Salicylate toxicity:** Salicylates have a low Vd and are small molecules. Hemodialysis is the gold standard for severe aspirin poisoning as it corrects acid-base imbalances while rapidly removing the drug. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for drugs NOT removed by dialysis (Large Vd):** **"V"**ery **"D"**istributed drugs like **V**erapamil, **D**igoxin, **D**iazepam, and Tricyclic Antidepressants (**TCA**). * **Mnemonic for drugs removed by dialysis:** **BLASTED** (**B**arbiturates, **L**ithium, **A**lcohol, **S**alicylates, **T**heophylline, **E**thylene glycol, **D**epakote/Valproate). * **Lithium** is a classic high-yield example of a drug easily removed by dialysis due to its very small size and lack of protein binding.
Question 382: Which of the following congenital malformations is seen in a child born to a mother treated with oral anticoagulants?
- A. Nasal hypoplasia (Correct Answer)
- B. Renal agenesis
- C. Long bone defects
- D. Achondroplasia
Explanation: **Explanation:** The correct answer is **Nasal hypoplasia**. This is a classic manifestation of **Fetal Warfarin Syndrome (Warfarin Embryopathy)**. **1. Why Nasal Hypoplasia is Correct:** Warfarin is a low-molecular-weight oral anticoagulant that easily crosses the placenta. When administered during the **first trimester (specifically 6–9 weeks of gestation)**, it interferes with the γ-carboxylation of osteocalcin and other bone proteins. This leads to defective cartilage and bone formation. The hallmark features include **nasal hypoplasia** (depressed nasal bridge) and **stippled epiphyses** (chondrodysplasia punctata) seen on X-ray. **2. Why the Other Options are Incorrect:** * **Renal agenesis:** This is typically associated with **ACE inhibitors** or ARBs (which cause oligohydramnios and Potter sequence), not oral anticoagulants. * **Long bone defects:** While warfarin affects bone, it specifically causes stippling of epiphyses rather than gross long bone defects. Limb hypoplasia is more characteristic of Thalidomide (Phocomelia). * **Achondroplasia:** This is a genetic (autosomal dominant) bone growth disorder caused by a mutation in the *FGFR3* gene, not by drug-induced teratogenicity. **3. NEET-PG High-Yield Pearls:** * **Safe Alternative:** **Heparin** (both UFH and LMWH) does **not** cross the placenta and is the anticoagulant of choice during pregnancy. * **Critical Period:** Warfarin exposure in the **second and third trimesters** is associated with CNS abnormalities (microcephaly, optic atrophy) and fetal hemorrhage. * **Vitamin K Antagonism:** Warfarin acts by inhibiting Vitamin K Epoxide Reductase (VKORC1). * **Key Triad of Warfarin Embryopathy:** Nasal hypoplasia, stippled epiphyses, and eye abnormalities.
Question 383: Which of the following drugs can cause osteonecrosis when administered intravenously?
- A. Zolendronate (Correct Answer)
- B. Dalteparin
- C. Calcitriol
- D. Zidovudine
Explanation: **Explanation:** **Zoledronate** (a potent intravenous bisphosphonate) is the correct answer. The underlying medical concept is **Medication-Related Osteonecrosis of the Jaw (MRONJ)**. Bisphosphonates inhibit osteoclast activity to prevent bone resorption. However, high-potency nitrogen-containing bisphosphonates like Zoledronate, especially when administered intravenously for bone metastases or Paget’s disease, can lead to impaired bone remodeling and decreased angiogenesis. This results in necrotic bone exposure in the maxillofacial region, typically following local trauma or dental surgery. **Analysis of Incorrect Options:** * **Dalteparin:** A Low Molecular Weight Heparin (LMWH) used as an anticoagulant. While long-term heparin use is associated with **osteoporosis**, it does not cause osteonecrosis. * **Calcitriol:** The active form of Vitamin D. It promotes calcium absorption and is used to treat hypocalcemia and metabolic bone disease; it is not associated with bone necrosis. * **Zidovudine:** A Nucleoside Reverse Transcriptase Inhibitor (NRTI) used in HIV. Its primary dose-limiting toxicity is **bone marrow suppression** (anemia/neutropenia) and myopathy, not osteonecrosis. **Clinical Pearls for NEET-PG:** * **MRONJ Risk Factors:** IV route (highest risk), long duration of therapy, and invasive dental procedures. * **Other Drugs:** Denosumab (RANKL inhibitor) and Anti-angiogenic agents (e.g., Bevacizumab) can also cause MRONJ. * **Management:** Patients should undergo a thorough dental examination and complete any necessary extractions *before* starting IV bisphosphonates. * **Zoledronate vs. Alendronate:** Zoledronate is given once yearly (IV) for osteoporosis, whereas Alendronate is given weekly (oral).
Question 384: Sclerosing cholangitis is a known side effect caused by which of the following drugs?
- A. Floxuridine (Correct Answer)
- B. Carbamazepine
- C. Sulfonamides
- D. Indinavir
Explanation: **Explanation:** **Floxuridine (Option A)** is the correct answer. It is a pyrimidine analog (a prodrug of 5-Fluorouracil) primarily used for the treatment of gastrointestinal cancers and hepatic metastases. When administered via **hepatic arterial infusion (HAI)** to achieve high local drug concentrations, it can cause chemical-induced biliary injury. This leads to **Sclerosing Cholangitis**, characterized by strictures of the biliary tree that mimic Primary Sclerosing Cholangitis (PSC). The mechanism involves ischemic injury to the bile ducts, as they receive their blood supply solely from the hepatic artery. **Analysis of Incorrect Options:** * **Carbamazepine (Option B):** Primarily associated with anticonvulsant hypersensitivity syndrome, Stevens-Johnson Syndrome (SJS/TEN), and idiosyncratic **cholestatic hepatitis**, but not sclerosing cholangitis. * **Sulfonamides (Option C):** These drugs typically cause hypersensitivity reactions, crystalluria, or **mixed hepatocellular-cholestatic injury**, but do not cause the structural biliary scarring seen with Floxuridine. * **Indinavir (Option D):** A protease inhibitor used in HIV treatment, it is classic for causing **nephrolithiasis** (kidney stones) due to drug crystallization in the urine, not biliary sclerosis. **High-Yield Clinical Pearls for NEET-PG:** * **Floxuridine:** Always associate "Hepatic Arterial Infusion" and "Biliary Sclerosis/Sclerosing Cholangitis" with this drug. * **Drug-Induced Liver Injury (DILI):** * *Pure Cholestasis:* Anabolic steroids, Oral Contraceptive Pills. * *Cholestatic Hepatitis:* Chlorpromazine, Erythromycin estolate. * *Sclerosing Cholangitis:* Floxuridine, Formaldehyde (if injected into hydatid cysts). * **Monitoring:** Patients on HAI Floxuridine require regular monitoring of Alkaline Phosphatase (ALP) and Bilirubin to detect early biliary toxicity.
Question 385: What is the treatment for Type II paralysis in organophosphorus poisoning?
- A. Atropine
- B. Oximes
- C. Symptomatic treatment (Correct Answer)
- D. No treatment
Explanation: **Explanation:** Organophosphorus (OP) poisoning typically presents in three distinct clinical phases. **Type II paralysis**, also known as **Intermediate Syndrome (IMS)**, occurs 24–96 hours after the acute cholinergic crisis. It is characterized by the paralysis of proximal limb muscles, neck flexors, and, most critically, respiratory muscles. **Why Symptomatic Treatment is Correct:** The underlying pathophysiology of Type II paralysis is believed to be **post-synaptic neuromuscular junction dysfunction** due to prolonged acetylcholinesterase inhibition. Unlike the initial acute phase, this stage does **not** respond to pharmacological reversal. The mainstay of treatment is **supportive/symptomatic care**, specifically **mechanical ventilation**, until neuromuscular transmission naturally recovers (usually within 5–15 days). **Analysis of Incorrect Options:** * **Atropine:** Atropine is a muscarinic antagonist. It is the life-saving treatment for the *Acute Cholinergic Crisis* (Type I) to reverse "wet" symptoms (SLUDGE), but it has no effect on the nicotinic receptors involved in muscle paralysis. * **Oximes (Pralidoxime):** While oximes are used in the acute phase to reactivate acetylcholinesterase, they are **ineffective** once Intermediate Syndrome has developed. In fact, inadequate oxime dosing during the acute phase is often cited as a risk factor for the development of Type II paralysis. * **No treatment:** This is incorrect as the condition is life-threatening due to respiratory failure; aggressive supportive care is mandatory. **NEET-PG High-Yield Pearls:** * **Type I (Acute Crisis):** Muscarinic symptoms; treat with Atropine + Oximes. * **Type II (Intermediate Syndrome):** Nicotinic symptoms (paralysis); treat with Ventilatory Support. * **Type III (OPIDN):** Delayed polyneuropathy (2–3 weeks later) due to inhibition of **Neuropathy Target Esterase (NTE)**; presents as "foot drop." * **Mnemonic:** Type II = "Two" days later = "Two" lungs (Respiratory failure).
Question 386: All of the following drugs require dose reduction in cirrhosis except?
- A. Lorazepam (Correct Answer)
- B. Diazepam
- C. Metronidazole
- D. Rifampicin
Explanation: **Explanation:** The liver is the primary site for drug metabolism, involving **Phase I** (Oxidation, Reduction, Hydrolysis via Cytochrome P450) and **Phase II** (Conjugation, e.g., Glucuronidation). In cirrhosis, Phase I reactions are significantly impaired, while Phase II reactions are relatively preserved until the very late stages of liver failure. **Why Lorazepam is the correct answer:** Lorazepam, along with Oxazepam and Temazepam (mnemonic: **LOT**), undergoes direct **Phase II Glucuronidation**. Since this pathway remains functional in cirrhotic patients, these drugs do not undergo significant accumulation and generally do not require dose reduction. They are the benzodiazepines of choice in patients with hepatic impairment or hepatic encephalopathy. **Analysis of Incorrect Options:** * **Diazepam:** It undergoes **Phase I** oxidative metabolism (hydroxylation and N-demethylation). In cirrhosis, its half-life is significantly prolonged, leading to accumulation and a high risk of over-sedation or coma. * **Metronidazole:** It is primarily metabolized by the liver via oxidation. In severe hepatic impairment, its clearance is reduced by nearly 50%, necessitating a dose reduction to prevent neurotoxicity. * **Rifampicin:** It is an enzyme inducer that is highly hepatotoxic and undergoes extensive enterohepatic circulation. It requires careful monitoring and dose adjustment in liver disease to prevent further hepatocyte injury. **High-Yield Clinical Pearls for NEET-PG:** * **Benzodiazepines in Liver Disease:** Use **LOT** (Lorazepam, Oxazepam, Temazepam) because they bypass Phase I metabolism. * **Phase I vs. Phase II:** Phase I (CYP450) is affected early in cirrhosis; Phase II (Conjugation) is "sturdier" and affected late. * **Enzyme Inducers:** Rifampicin can worsen hepatic conditions by increasing the production of toxic metabolites of other drugs (e.g., Paracetamol).
Question 387: What is the mechanism of action of pralidoxime?
- A. Stimulation of acetylcholine receptors
- B. Inhibition of the breakdown of acetylcholine
- C. Blockade of acetylcholine receptors
- D. Reactivation of acetylcholinesterase enzyme (Correct Answer)
Explanation: **Explanation:** **Mechanism of Action (Correct Answer: D)** Pralidoxime (2-PAM) belongs to a class of drugs known as **cholinesterase reactivators**. In Organophosphate (OP) poisoning, the organophosphate molecule binds to the anionic site of the acetylcholinesterase (AChE) enzyme, phosphorylating it and rendering it inactive. Pralidoxime has a high affinity for the anionic site; it binds to the enzyme, attracts the phosphate group away from the serine residue, and releases the regenerated, active enzyme. This process must occur before **"aging"** (the permanent dealkylation of the enzyme-phosphate complex) takes place. **Analysis of Incorrect Options:** * **Option A:** Pralidoxime does not stimulate receptors; its role is purely enzymatic restoration. * **Option B:** This describes the effect of Organophosphates or Carbamates themselves, which lead to an "acetylcholine storm." Pralidoxime reverses this inhibition. * **Option C:** This is the mechanism of **Atropine**, which competitively blocks muscarinic receptors to treat the symptoms of OP poisoning. **NEET-PG High-Yield Pearls:** * **The "Aging" Concept:** Pralidoxime is ineffective once the enzyme has "aged." Therefore, it must be administered early (usually within 24–48 hours). * **Atropine vs. Oximes:** Atropine treats **muscarinic** symptoms (miosis, bradycardia, secretions) but does not fix muscle paralysis. Pralidoxime is essential because it treats **nicotinic** symptoms (muscle weakness/paralysis) by regenerating the enzyme at the neuromuscular junction. * **Contraindication:** Pralidoxime is generally **not** recommended for **Carbamate poisoning** (e.g., Sevin) because the carbamate-enzyme bond is reversible and short-lived; in some cases (like Neostigmine), oximes may even worsen the toxicity.
Question 388: Which of the following is used to treat cyanide poisoning?
- A. Pyridoxine
- B. Vitamin B12 (Correct Answer)
- C. Hyperbaric oxygen
- D. Flumazenil
Explanation: **Explanation:** **Cyanide poisoning** occurs due to the inhibition of **Cytochrome oxidase a3** in the electron transport chain, leading to cellular hypoxia and lactic acidosis. **Why Vitamin B12 is the correct answer:** The specific form of Vitamin B12 used is **Hydroxocobalamin**. It acts as a direct antidote by binding to cyanide ions with high affinity to form **Cyanocobalamin** (a non-toxic form of Vitamin B12), which is then safely excreted by the kidneys. It is currently preferred over the traditional "Cyanide Antidote Kit" (Nitrites + Sodium Thiosulfate) because it does not induce methemoglobinemia, making it safer for patients with concomitant carbon monoxide poisoning (common in fire victims). **Analysis of Incorrect Options:** * **A. Pyridoxine (Vitamin B6):** Used as an antidote for **Isoniazid (INH)** toxicity and Ethylene glycol poisoning. * **C. Hyperbaric Oxygen:** While 100% oxygen is supportive in cyanide poisoning, hyperbaric oxygen is the definitive treatment for **Carbon Monoxide (CO)** poisoning. * **D. Flumazenil:** A specific competitive antagonist used for **Benzodiazepine** overdose. **High-Yield Clinical Pearls for NEET-PG:** * **Classic Presentation:** Bitter almond odor on breath, cherry-red skin (early), and severe metabolic acidosis. * **Traditional Antidote Kit:** 1. **Amyl/Sodium Nitrite:** Creates methemoglobin, which pulls cyanide away from cytochrome oxidase. 2. **Sodium Thiosulfate:** Provides a sulfur donor for the enzyme **Rhodanese** to convert cyanide into less toxic Thiocyanate. * **Drug-Induced Toxicity:** Sodium Nitroprusside infusion can lead to cyanide toxicity; it is often co-administered with Sodium Thiosulfate to prevent this.
Question 389: What drug is associated with the following adverse drug reaction (ADR)?
- A. Chloramphenicol
- B. Demeclocycline (Correct Answer)
- C. Erythromycin
- D. Daptomycin
Explanation: ***Demeclocycline*** - A **tetracycline antibiotic** that causes **photosensitivity reactions** due to its ability to absorb UV light and generate reactive oxygen species in the skin. - The **phototoxic dermatitis** appears as sunburn-like lesions on **sun-exposed areas** such as face, neck, and hands. *Chloramphenicol* - Primary adverse effects include **bone marrow suppression** leading to aplastic anemia and **gray baby syndrome** in neonates. - **Not associated** with photosensitivity reactions; its toxicity is mainly hematological and hepatic. *Erythromycin* - Commonly causes **gastrointestinal upset** (nausea, vomiting, diarrhea) and **hepatotoxicity** with prolonged use. - **Photosensitivity** is not a recognized adverse effect of this macrolide antibiotic. *Daptomycin* - Major adverse effects include **myopathy** with elevated creatine kinase levels and **eosinophilic pneumonia**. - **No association** with photosensitivity; monitoring focuses on muscle toxicity and pulmonary symptoms.
Question 390: Which of the following drugs exhibits a therapeutic window phenomenon?
- A. Carbamazepine (Correct Answer)
- B. Diazepam
- C. Chlorpromazine
- D. Clonidine
Explanation: ### Explanation The **therapeutic window phenomenon** refers to a specific pharmacological situation where a drug is effective only within a narrow range of plasma concentrations. If the dose is too low, it is ineffective; if the dose is too high, the therapeutic effect is lost (not just increased toxicity, but a decrease in efficacy). **1. Why Carbamazepine is Correct:** Carbamazepine is a classic example of a drug with a **narrow therapeutic index** and a defined therapeutic window (typically 4–12 µg/mL). In clinical practice, especially in the treatment of trigeminal neuralgia and epilepsy, the drug must be maintained within this specific range. While many drugs show increased toxicity at high doses, Carbamazepine is frequently cited in competitive exams alongside **Tricyclic Antidepressants (TCAs) like Nortriptyline** and **Glidants** as drugs exhibiting this phenomenon. **2. Analysis of Incorrect Options:** * **Diazepam:** This is a Benzodiazepine with a very **wide therapeutic index**. It follows a standard dose-response curve where increasing the dose increases the effect (sedation → hypnosis → anesthesia) without a loss of efficacy at higher levels. * **Chlorpromazine:** As a typical antipsychotic, it has a wide safety margin regarding its primary therapeutic effect. While it has many side effects (Extrapyramidal symptoms), it does not lose its antipsychotic efficacy at higher doses. * **Clonidine:** This is an alpha-2 agonist used for hypertension. It follows a predictable dose-response relationship; it does not exhibit a "window" where it stops lowering blood pressure at higher doses. **3. NEET-PG High-Yield Pearls:** * **Classic Examples:** The most frequently asked drugs with a therapeutic window are **Nortriptyline, Carbamazepine, and Clonidine** (in specific experimental contexts, though Carbamazepine is the preferred answer here). * **Therapeutic Index (TI):** Calculated as $LD_{50} / ED_{50}$. A low TI requires **Therapeutic Drug Monitoring (TDM)**. * **TDM Drugs:** Remember the mnemonic **"LiTe DeCaF"** — **Li**thium, **Te**mporal lobe drugs (Phenytoin/Carbamazepine), **De**merol (Pethidine), **Ca**rdiac glycosides (Digoxin), **F**lecanide/Phenobarbital.
Practice by Chapter
Principles of Clinical Pharmacology
Practice Questions
Therapeutic Drug Monitoring
Practice Questions
Drug Toxicity and Overdose
Practice Questions
Antidotes and Their Applications
Practice Questions
Management of Drug Poisoning
Practice Questions
Drug-Induced Liver Injury
Practice Questions
Drug-Induced Kidney Injury
Practice Questions
Drug-Induced Blood Dyscrasias
Practice Questions
Drug-Induced QT Prolongation
Practice Questions
Pharmacovigilance
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free